Profile data is unavailable for this security.
About the company
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).
- Revenue in USD (TTM)0.00
- Net income in USD-34.36m
- Incorporated2015
- Employees14.00
- LocationCalciMedica Inc505 Coast Boulevard South, Suite 307LA JOLLA 92037United StatesUSA
- Phone+1 (858) 952-5500
- Fax+1 (302) 655-5049
- Websitehttps://calcimedica.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics Inc | 13.79m | -99.59m | 57.04m | 66.00 | -- | -- | -- | 4.14 | -1.50 | -1.50 | 0.1783 | -- | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -9.00 | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Immix Biopharma Inc | 0.00 | -15.43m | 57.56m | 14.00 | -- | 2.65 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.8235 | 0.00 | -- | -- | 0.00 | -89.54 | -- | -103.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 58.96m | 134.00 | 4.98 | 0.2359 | 1.80 | 0.2289 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 59.28m | 217.00 | -- | 0.4376 | -- | 18.65 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -34.36m | 60.14m | 14.00 | -- | 3.91 | -- | -- | -26.09 | -26.09 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -132.51 | -63.99 | -155.72 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Bakhu Holdings Corp | 0.00 | -1.92m | 60.26m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 60.49m | 8.00 | -- | 0.7446 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Kronos Bio Inc | 6.29m | -112.67m | 61.30m | 62.00 | -- | 0.378 | -- | 9.75 | -1.95 | -1.95 | 0.1089 | 2.70 | 0.0248 | -- | -- | 101,419.40 | -44.34 | -35.47 | -48.77 | -37.14 | -- | -- | -1,791.87 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Carisma Therapeutics Inc | 15.07m | -81.22m | 61.48m | 107.00 | -- | 5.64 | -- | 4.08 | -2.01 | -2.01 | 0.3723 | 0.2623 | 0.1311 | -- | -- | 140,869.20 | -70.64 | -30.87 | -83.17 | -34.47 | -- | -- | -538.81 | -255.66 | -- | -- | 0.1717 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Protara Therapeutics Inc | 0.00 | -42.47m | 61.77m | 26.00 | -- | 0.5873 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 63.69m | 9.00 | -- | 3.25 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Atara Biotherapeutics Inc | 34.70m | -233.11m | 63.81m | 173.00 | -- | -- | -- | 1.84 | -2.12 | -2.12 | 0.3016 | -0.817 | 0.1485 | 0.9947 | 1.92 | 154,240.00 | -99.76 | -70.20 | -213.09 | -86.94 | 69.30 | -- | -671.70 | -1,559.33 | 0.50 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Mural Oncology PLC | 0.00 | -207.45m | 63.97m | 117.00 | -- | 0.2391 | -- | -- | -12.43 | -12.43 | 0.00 | 15.81 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Data as of May 10 2024. Currency figures normalised to CalciMedica Inc's reporting currency: US Dollar USD
11.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Stonepine Capital Management LLCas of 22 Jan 2024 | 522.60k | 4.87% |
| Aisling Capital Management LPas of 23 Jan 2024 | 521.11k | 4.85% |
| BML Capital Management LLCas of 31 Mar 2024 | 160.42k | 1.49% |
| Meritage Portfolio Management, Inc.as of 31 Mar 2024 | 46.00k | 0.43% |
| Geode Capital Management LLCas of 31 Dec 2023 | 13.35k | 0.12% |
| First Manhattan Co LLCas of 31 Dec 2023 | 13.23k | 0.12% |
| Tower Research Capital LLCas of 31 Dec 2023 | 1.42k | 0.01% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 749.00 | 0.01% |
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 506.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 107.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
